CHAMP Trial Shows Promise for Aggressive Prostate Cancer with Chemoimmunotherapy

Patients with neuroendocrine and aggressive-variant prostate cancer historically face median survival under one year; this trial offers potential to extend survival and improve outcomes for this high-mortality population.

In the long struggle against prostate cancer's most unforgiving forms, a trial presented in Chicago this June offered something rare: a reason for measured hope. The CHAMP trial combined chemotherapy with dual immunotherapy for men whose neuroendocrine and aggressive-variant prostate cancers had historically offered median survival of less than a year, and found that 74 percent remained free of radiographic progression at six months — a statistically significant leap beyond what platinum chemotherapy alone has historically achieved. It is not yet proof of cure, nor even of extended survival, b

CHAMP Trial Shows Promise for Aggressive Prostate Cancer with Chemoimmunotherapy

Cobertura Relacionada

Receba o Register no seu e-mail